Cairns Linda, Curigliano Giuseppe
European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.
Ecancermedicalscience. 2016 Feb 2;10:618. doi: 10.3332/ecancer.2016.618. eCollection 2016.
The 2015 San Antonio Breast Cancer Symposium (SABCS) annual meeting highlighted the latest discoveries in breast cancer research and as ever provided a unique opportunity for investigators from all over the world to meet and network. With the rapidly increasing pace of discoveries in the basic, translational, and clinical sciences, mainly because of the advent of new technologies, cancer researchers are making rapid progress that is having significant patient benefit. This year's meeting featured studies on targeted therapy plus endocrine therapy for metastatic disease with a mutation of PIK3CA, chemotherapy combinations for HER-2-positive disease, long-term outcomes of different surgeries for early-stage cancers, and the first-ever trial of a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor as an adjuvant treatment for breast cancer in postmenopausal women. In the educational session, there was significant emphasis on the role of metabolic syndrome and lifestyle on breast cancer outcome.
2015年圣安东尼奥乳腺癌研讨会（SABCS）年会突出了乳腺癌研究的最新发现，一如既往地为来自世界各地的研究人员提供了一个见面和交流的独特机会。由于新技术的出现，基础、转化和临床科学领域的发现步伐迅速加快，癌症研究人员正在取得迅速进展，这给患者带来了显著益处。今年的会议展示了针对携带PIK3CA突变的转移性疾病的靶向治疗加内分泌治疗、HER-2阳性疾病的化疗联合方案、早期癌症不同手术方式的长期结果，以及首次将核因子κB受体活化因子配体（RANKL）抑制剂作为绝经后女性乳腺癌辅助治疗的试验。在教育环节，重点显著强调了代谢综合征和生活方式对乳腺癌预后的作用。
